ENDPOINTS NEWS4m
Sen. Cas­sidy ques­tions Lil­ly and Am­gen on 340B re­stric­tions on con­tract phar­ma­cies
As the fed­er­al gov­ern­ment is threat­en­ing John­son & John­son with fines re­lat­ed to its uni­lat­er­al al­ter­ations to ...
ENDPOINTS NEWS39m
Over a year af­ter FDA re­jec­tion, Bio­haven claims suc­cess in piv­otal mus­cle dis­ease study
Biohaven is seeking to reverse the fate of its embattled experimental drug troriluzole in spinocerebellar ataxia — a ...
ENDPOINTS NEWS1h
UCB adds three more FDA ap­provals to la­bel for po­ten­tial block­buster Bimzelx
UCB’s Bimzelx scored three more FDA approvals on Monday, making it the first and only IL-17A and IL-17F inhibitor approved in ...
ENDPOINTS NEWS4h
Q&A: Bris­tol My­ers’ tech chief on the promis­es and per­ils of AI bio
For AI-focused startups seeking out pharma deals, they have to go through people like Greg Meyers, the chief digital and ...
ENDPOINTS NEWS4h
Is Sanofi mak­ing a move in­to obe­si­ty? French phar­ma in­vests $27M in­to Ven­tyx
Sanofi has stayed out of the obesity drug development bonanza, taking a wait-and-see approach while keeping an eye on ...
ENDPOINTS NEWS4h
Black Di­a­mond treads wa­ter on small snap­shot of Phase 2 lung can­cer da­ta
Black Diamond Therapeutics’ stock price $BDTX jumped more than 15% premarket Monday morning after the company reported its ...
ENDPOINTS NEWS5h
Telix buys ra­dio­phar­ma­cy net­work for $230M up front to ex­pand US ca­pac­i­ty
Australian radiopharma company Telix Pharmaceuticals is acquiring radioisotope manufacturer RLS Radiopharmacies in another ...
ENDPOINTS NEWS7h
Ideaya out­lines reg­u­la­to­ry path for rare eye can­cer drug af­ter pos­i­tive mid-stage da­ta
Ideaya Biosciences has set the stage on what a Phase 3 trial would look like for its rare eye cancer drug darovasertib, after ...
ENDPOINTS NEWS7h
As­traZeneca, Dai­ichi’s TROP2 drug miss­es over­all sur­vival goal in Phase 3 breast can­cer tri­al
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate failed a key survival endpoint in a late-phase breast ...
ENDPOINTS NEWS6h
Up­dat­ed: FDA ap­proves Zevra’s rare dis­ease drug af­ter re­sub­mis­sion
After a second review, the FDA approved Zevra Therapeutics’ treatment for Niemann-Pick disease type C, a progressive rare ...
ENDPOINTS NEWS11h
UK vac­cine start­up Vice­bio snags $100M to take on GSK, Pfiz­er and Mod­er­na
The former head of vaccine R&D at GSK has pulled together $100 million for a London-based biotech working on respiratory ...
ENDPOINTS NEWS3h
Con­text makes a T cell en­gager deal; Gink­go Bioworks back­ers have a new SPAC
Plus, news about Longevity Biomedical, Sensorion, Teva and Bristol Myers Squibb: Context Therapeutics buys a T cell engager: The biotech will pay $15 million upfront and up to $118.5 million in ...